• Plans reported managing cancer therapies in a variety of ways as shown in Figure 5 (N=45) Figure 5 : Management of Cancer Care
• Oncology genomic tests were covered by 87.7% of plans (compared with 90.2% last year) • Cancer/oncology was consistently reported the top concern from medical and budgetary points of view ( Figure 6 ) • Compared with last year's survey, the percent citing cancer/oncology as a top concern from a: o Medical point of view in 2016 decreased from 50%, in 5 years (2021) increased by 7.5% from 42.5% o Budgetary point of view in 2016 increased 14.3% (from 35.7%) and
in 5 years (2021) increased by 3.4% Figure 1) , and the most common degree was MD (57%). 86% of the respondents were involved in formulary decisions 
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